×
About 6,038 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  2,899 results

Anatomic-Functional Correlates in Lesions of Retinal Vein Occlusion.
https://doi.org/10.1167/iovs.62.7.10
Investigative Ophthalmology & Visual Science; Khayat M, Perais J et. al.

Jun 8th, 2021 - To evaluate anatomic-functional associations at sites of retinal lesions in retinal vein occlusion (RVO). This pilot, prospective, observational study was conducted at the Northern Ireland Clinical Research Facility (NICRF) of Queen's University a...

Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164284
Journal of Medical Case Reports; Nowrouzi A, Kafiabasabadi S et. al.

May 29th, 2021 - We report our findings in a patient who developed central retinal vein occlusion (CRVO) and was a chronic user of olanzapine, an antipsychotic medication. A 50-year-old Caucasian man, non-smoker, was referred to our clinic with the chief complaint...

Racial Differences in Anti-VEGF Intravitreal Injections Among Commercially Insured Bene...
https://doi.org/10.3928/23258160-20210330-05
Ophthalmic Surgery, Lasers & Imaging Retina; Al-Moujahed A, Vail D et. al.

May 27th, 2021 - This study assessed racial and ethnic differences in receiving anti-vascular endothelial growth factor (VEGF) intravitreal injections among commercially insured patients. A retrospective cohort study of 104,430 patients diagnosed with wet age-rela...

The clinical relevance of ultra-widefield angiography findings in patients with central...
https://doi.org/10.1038/s41433-021-01553-7 10.1016/j.ajo.2017.07.015 10.1016/j.ophtha.2011.02.038 10.1097/IAE.0000000000000191 10.1016/j.ajo.2015.09.003 10.2307/2529310 10.1136/bjo.60.6.411 10.1001/archopht.119.12.1781 10.1034/j.1600-0420.2002.800506.x 10.1016/j.ophtha.2010.01.060 10.1007/BF00176435 10.1097/IAE.0000000000000277 10.1177/112067210301300505 10.1016/j.ophtha.2009.08.022
Eye (London, England); Nicholson L, Vazquez-Alfageme C et. al.

May 26th, 2021 - To report, using ultra-widefield angiography (UWFA) the area, distribution, and change in retinal capillary nonperfusion (RCNP) at baseline and 100 weeks in eyes with central retinal vein occlusion (CRVO) receiving anti-VEGF for macula oedema. Pro...

see more →

Guidelines  1 results

Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the A...
https://www.aaojournal.org/article/S0161-6420(17)30980-6/fulltext
Justis P. Ehlers

Aug 31st, 2017 - Current level I evidence suggests that intravitreal pharmacotherapy with anti-VEGF agents is effective and safe for ME secondary to BRVO. Prolonged delay in treatment is associated with less improvement in visual acuity (VA).

see more →

Drugs  4 results see all →

Clinicaltrials.gov  3,023 results

Anatomic-Functional Correlates in Lesions of Retinal Vein Occlusion.
https://doi.org/10.1167/iovs.62.7.10
Investigative Ophthalmology & Visual Science; Khayat M, Perais J et. al.

Jun 8th, 2021 - To evaluate anatomic-functional associations at sites of retinal lesions in retinal vein occlusion (RVO). This pilot, prospective, observational study was conducted at the Northern Ireland Clinical Research Facility (NICRF) of Queen's University a...

Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164284
Journal of Medical Case Reports; Nowrouzi A, Kafiabasabadi S et. al.

May 29th, 2021 - We report our findings in a patient who developed central retinal vein occlusion (CRVO) and was a chronic user of olanzapine, an antipsychotic medication. A 50-year-old Caucasian man, non-smoker, was referred to our clinic with the chief complaint...

Racial Differences in Anti-VEGF Intravitreal Injections Among Commercially Insured Bene...
https://doi.org/10.3928/23258160-20210330-05
Ophthalmic Surgery, Lasers & Imaging Retina; Al-Moujahed A, Vail D et. al.

May 27th, 2021 - This study assessed racial and ethnic differences in receiving anti-vascular endothelial growth factor (VEGF) intravitreal injections among commercially insured patients. A retrospective cohort study of 104,430 patients diagnosed with wet age-rela...

The clinical relevance of ultra-widefield angiography findings in patients with central...
https://doi.org/10.1038/s41433-021-01553-7 10.1016/j.ajo.2017.07.015 10.1016/j.ophtha.2011.02.038 10.1097/IAE.0000000000000191 10.1016/j.ajo.2015.09.003 10.2307/2529310 10.1136/bjo.60.6.411 10.1001/archopht.119.12.1781 10.1034/j.1600-0420.2002.800506.x 10.1016/j.ophtha.2010.01.060 10.1007/BF00176435 10.1097/IAE.0000000000000277 10.1177/112067210301300505 10.1016/j.ophtha.2009.08.022
Eye (London, England); Nicholson L, Vazquez-Alfageme C et. al.

May 26th, 2021 - To report, using ultra-widefield angiography (UWFA) the area, distribution, and change in retinal capillary nonperfusion (RCNP) at baseline and 100 weeks in eyes with central retinal vein occlusion (CRVO) receiving anti-VEGF for macula oedema. Pro...

see more →

News  109 results

Retinal Vein Occlusion Clinical Practice Guidelines (2019)
https://reference.medscape.com/viewarticle/917394

Sep 2nd, 2019 - In August 2019, the European Society of Retina Specialists (EURETINA) published clinical practice guidelines on the management of retinal vein occlusion (RVO).[1] Patients with suspected retinal vein occlusion (RVO) should undergo a full ophthalmo...

FDA Okays Aflibercept (Eylea) for Diabetic Retinopathy
https://www.staging.medscape.com/viewarticle/913006

May 13th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron Pharmaceuticals) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor...

FDA OKs Aflibercept (Eylea) for Diabetic Retinopathy
https://www.medscape.com/viewarticle/913006

May 13th, 2019 - The US Food and Drug Administration (FDA) has approved aflibercept (Eylea, Regeneron) injection solution to treat all stages of diabetic retinopathy, the manufacturer has announced. Aflibercept, a vascular endothelial growth factor (VEGF) inhibito...

Anti-VEGF Tx Seems OK for Eye Disorders
https://www.medpagetoday.com/ophthalmology/generalophthalmology/71990

Mar 25th, 2018 - Intravitreal anti-VEGF treatments for neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion did not appear to increase the risk of systemic adverse events, particularly cardiovascular adverse e...

A Guide To Managing RVO: Ophthalmology Times
https://www.medpagetoday.com/ophthalmology/generalophthalmology/70255

Jan 2nd, 2018 - One expert discusses options for managing retinal vein occlusion over the long-term in patients with macular edema. A recent study reported that visual acuity did not improve when patients with diabetic macular edema received corticosteroid implan...

see more →

Patient Education  2 results see all →